Welcome to the Future of Grocery Shopping: Uber Eats Partners with Wegmans! Convenience at Your Doorstep Imagine this: it’s winter, you’re hosting a game day celebration, and you realize you forgot a key ingredient for your famous buffalo chicken dip. In the past, you might have had to scramble to the nearest grocery store or…
A Letter from NEXE Innovations Inc. to Shareholders Windsor, ON – Jan. 23, 2025 Hey there, NEXE shareholders! It’s your friendly neighborhood President, Ash Guglani, here to chat about all things innovation and compostable materials. 2024 was quite a year for us at NEXE Innovations, and we’re gearing up for even more excitement in 2025….
Marimekko Corporation, Press Release 23 January 2025 at 3.00 p.m. EET Hey there fellow Marimekko enthusiasts! Have you heard the exciting news? The Science Based Target initiative (SBTi) has given their stamp of approval on Marimekko’s emission reduction targets. What does this mean exactly? Well, let me break it down for you in my own…
Welcome to the Checkpoint Sustainment Contract Buzz! Say What? Leidos Strikes Again! So, have you heard the latest buzz in the tech world? Reston-based company Leidos has just announced a follow-on checkpoint sustainment contract to keep thousands of Transportation Security Equipment (TSE) units up and running in airports across the U.S. and its territories. That’s…
Welcome to Aspen Aerogels Blog Exciting News from Aspen Aerogels NORTHBOROUGH, Mass. , Jan. 23, 2025 /PRNewswire/ — Aspen Aerogels, Inc. (NYSE: ASPN) Aspen Aerogels is proud to announce that Don Young, President & Chief Executive Officer, and Ricardo C. have made a groundbreaking announcement today. This news is set to change the game in…
ALX Oncology Announces Positive Data from ASPEN-06 Phase 2 Clinical Trial Exciting News for Cancer Treatment SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives,…
Genprex Announces Enrollment of First Patient in Phase 2 Expansion Study Acclaim-3 Study Progresses Towards Interim Analysis AUSTIN, Texas , Jan. 23, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient…
The Schwab U.S. Dividend Equity ETF: A Smart Investment Choice What is SCHD? The Schwab U.S. Dividend Equity ETF (SCHD) is a popular exchange-traded fund that offers automatic diversification, income, and growth opportunities for investors. One of the key highlights of this ETF is its attractive 3.5% dividend yield, providing investors with a steady stream…
